Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRVI Maravai LifeSciences	$2.20 +8.4%	$2.39	$1.66 ▼ $9.95	$515.69M	0.28	1.54 million shs	1.58 million shs
NVCT Nuvectis Pharma	$6.00 -2.8%	$7.90	$4.44 ▼ $11.80	$157.07M	-0.26	226,409 shs	177,460 shs
TSHA Taysha Gene Therapies	$2.72 -3.2%	$2.59	$1.05 ▼ $3.31	$603.20M	0.98	2.76 million shs	1.10 million shs
XNCR Xencor	$7.23 -1.2%	$8.67	$7.07 ▼ $27.24	$522.09M	0.89	608,290 shs	872,504 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRVI Maravai LifeSciences	+8.37%	-0.90%	-20.29%	+10.55%	-75.82%
NVCT Nuvectis Pharma	-2.76%	-11.76%	-25.74%	-33.26%	-9.64%
TSHA Taysha Gene Therapies	-3.20%	+3.42%	+7.09%	+27.70%	+33.99%
XNCR Xencor	-1.23%	-9.40%	-22.51%	-13.21%	-53.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MRVI Maravai LifeSciences	3.6234 of 5 stars	3.1	1.0	4.4	1.8	0.8	1.3
NVCT Nuvectis Pharma	2.5007 of 5 stars	3.5	0.0	0.0	1.4	5.0	0.6
TSHA Taysha Gene Therapies	2.976 of 5 stars	4.5	0.0	0.0	3.0	3.3	0.0
XNCR Xencor	3.497 of 5 stars	3.4	0.0	3.9	1.9	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRVI Maravai LifeSciences	2.25	Hold	$6.64	201.77% Upside
NVCT Nuvectis Pharma	3.00	Buy	$15.33	155.56% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.17	200.25% Upside
XNCR Xencor	2.75	Moderate Buy	$26.43	265.54% Upside

Current Analyst Ratings Breakdown

Latest NVCT, XNCR, MRVI, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	XNCR Xencor	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $27.00
8/7/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$31.00 ➝ $26.00
8/4/2025	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
7/11/2025	TSHA Taysha Gene Therapies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRVI Maravai LifeSciences	$259.18M	2.16	$0.67 per share	3.28	$2.28 per share	0.96
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.66 per share	N/A
TSHA Taysha Gene Therapies	$8.33M	70.09	N/A	N/A	$0.35 per share	7.77
XNCR Xencor	$110.49M	4.67	N/A	N/A	$8.70 per share	0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRVI Maravai LifeSciences	-$144.85M	-$1.14	N/A	N/A	N/A	-67.14%	-12.91%	-6.87%	8/11/2025 (Estimated)
NVCT Nuvectis Pharma	-$19M	-$1.17	N/A	N/A	N/A	N/A	-150.81%	-94.84%	N/A
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/12/2025 (Estimated)
XNCR Xencor	-$232.62M	-$3.06	N/A	N/A	N/A	-121.52%	-25.75%	-18.19%	N/A

Latest NVCT, XNCR, MRVI, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	TSHA Taysha Gene Therapies	-$0.07	N/A	N/A	N/A	$1.61 million	N/A
8/11/2025	Q2 2025	MRVI Maravai LifeSciences	-$0.06	N/A	N/A	N/A	$47.46 million	N/A
8/6/2025	Q2 2025	XNCR Xencor	-$0.78	-$0.41	+$0.37	-$0.41	$22.59 million	$43.61 million
8/5/2025	Q2 2025	NVCT Nuvectis Pharma	-$0.25	-$0.30	-$0.05	-$0.30	N/A	N/A
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRVI Maravai LifeSciences	0.60	5.96	5.17
NVCT Nuvectis Pharma	N/A	2.66	3.28
TSHA Taysha Gene Therapies	0.77	5.35	5.35
XNCR Xencor	N/A	5.34	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MRVI Maravai LifeSciences	50.25%
NVCT Nuvectis Pharma	96.77%
TSHA Taysha Gene Therapies	77.70%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
MRVI Maravai LifeSciences	2.11%
NVCT Nuvectis Pharma	30.52%
TSHA Taysha Gene Therapies	3.78%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MRVI Maravai LifeSciences	610	254.66 million	249.29 million	Optionable
NVCT Nuvectis Pharma	8	25.46 million	17.69 million	Not Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable
XNCR Xencor	280	71.32 million	67.78 million	Optionable

NVCT, XNCR, MRVI, and TSHA Headlines

Recent News About These Companies

Xencor (XNCR) Q2 Revenue Jumps 82%

August 9 at 5:37 AM | theglobeandmail.com

Xencor (NASDAQ:XNCR) Hits New 12-Month Low Following Analyst Downgrade

August 9 at 2:09 AM | americanbankingnews.com

Xencor (NASDAQ:XNCR) Hits New 12-Month Low on Analyst Downgrade

August 8 at 11:55 AM | marketbeat.com

Xencor (NASDAQ:XNCR) Given New $27.00 Price Target at Wells Fargo & Company

August 8 at 11:52 AM | marketbeat.com

Wedbush Lowers Xencor (NASDAQ:XNCR) Price Target to $26.00

August 8 at 10:11 AM | marketbeat.com

Xencor price target lowered to $26 from $31 at Wedbush

August 8 at 9:32 AM | finance.yahoo.com

Primecap Management Co. CA Has $103.86 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

August 8 at 5:39 AM | marketbeat.com

XTX Topco Ltd Acquires 35,627 Shares of Xencor, Inc. (NASDAQ:XNCR)

August 7 at 3:38 AM | marketbeat.com

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

August 6 at 6:36 PM | zacks.com

Xencor (XNCR) to Release Earnings on Monday

August 3, 2025 | americanbankingnews.com

Short Interest in Xencor, Inc. (NASDAQ:XNCR) Rises By 127,291.3%

August 3, 2025 | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Short Interest Update

August 2, 2025 | marketbeat.com

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

July 31, 2025 | finance.yahoo.com

Analysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $28.00

July 31, 2025 | americanbankingnews.com

Xencor (XNCR) Projected to Post Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Invests $528,000 in Xencor, Inc. (NASDAQ:XNCR)

July 28, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by Brokerages

July 28, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Stock Price Down 4.3% - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Shares Pass Above 50 Day Moving Average - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading 7.3% Higher - What's Next?

July 9, 2025 | marketbeat.com

Xencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo Finance

June 29, 2025 | ca.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT, XNCR, MRVI, and TSHA Company Descriptions

Maravai LifeSciences NASDAQ:MRVI

$2.20 +0.17 (+8.37%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.32 +0.12 (+5.50%)

As of 08/8/2025 07:43 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Nuvectis Pharma NASDAQ:NVCT

$6.00 -0.17 (-2.76%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$6.00 0.00 (-0.08%)

As of 08/8/2025 04:29 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Taysha Gene Therapies NASDAQ:TSHA

$2.72 -0.09 (-3.20%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.75 +0.03 (+1.25%)

As of 08/8/2025 07:56 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Xencor NASDAQ:XNCR

$7.23 -0.09 (-1.23%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$7.24 +0.00 (+0.07%)

As of 08/8/2025 06:23 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time